| Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma CE Wu, A Esfandiari, YH Ho, N Wang, AK Mahdi, E Aptullahoglu, P Lovat, ... British journal of cancer 118 (4), 495-508, 2018 | 55 | 2018 |
| Key features of the environment promoting liver cancer in the absence of cirrhosis MYW Zaki, AK Mahdi, GL Patman, A Whitehead, JP Maurício, MV McCain, ... Scientific reports 11 (1), 16727, 2021 | 11 | 2021 |
| Inhibition of WIP1/PPM1D phosphatase by GSK2830371 potentiates the growth inhibitory and cytotoxic activity of MDM2 antagonists (nutlin-3, RG7388 and HDM201) in cutaneous … CE Wu, A Esfandiari, YH Ho, C Shepherd, AK Mahdi, E Aptullahoglu, ... Cancer Research 77 (13_Supplement), 2151-2151, 2017 | 1 | 2017 |
| Abstract P3-07-21: Cytotoxic potential of the RG7388 MDM2-p53 binding antagonist and the GSK2830371 WIP1 inhibitor on MX-1 and MCF-7 human breast cancer cells V Manoharan, J Lunec, A Esfandiari, A Mahdi, CE Wu, M Zanjirband, ... Cancer Research 77 (4_Supplement), P3-07-21-P3-07-21, 2017 | 1 | 2017 |
| Lymphocyte Predominance Hodgkin Lymphoma Clincopathological and Immunohistochemical Interpretations Using CD15 and CD20 YE Abdul-Qadir, AK Chaloob, AK Mahdi Iraqi Postgraduate Medical Journal 7 (3), 2008 | 1 | 2008 |
| OP-01 Genome wide RNA expression analysis identifies CD44 positive macrophages as promoters of hepatocyte proliferation and the development of NAFLD-HCC HLR Marco Youssef William Zaki, Misti V McCain, Ahmed K Mahdi, Joao Mauricio ... EASL HCC summit 2019, 2019 | | 2019 |
| Liquid Biopsy-A New Prospect. AK Mahdi Iraqi Journal of Medical Sciences 16 (4), 2018 | | 2018 |
| What drives development of HCC in non-cirrhotic NAFLD? A Mahdi, M Zaki, J Lunec, Q Anstee, D Tiniakos, R Shukla, F Oakley, ... Journal of Hepatology 68, S49, 2018 | | 2018 |
| Molecular pathology: the roles of P53 in the oxidative stress and DNA damage responses in chronic liver disease and hepatocellular carcinoma AK Mahdi Newcastle University, 2018 | | 2018 |
| Lipogranulomas, neutrophils and the progression of NAFLD to NASH and HCC JC Mauricio, AK Mahdi, J Lunec, G Patman, A Whitehead, D Tiniakos, ... HEPATOLOGY 66, 987A-988A, 2017 | | 2017 |
| MDM2 inhibition for non-genotoxic activation of TP53-a novel strategy for the treatment of hepatocellular carcinoma (HCC) AK Mahdi, HD Thomas, S Wedge, R Shukla, H Reeves, J Lunec HEPATOLOGY 66, 369A-369A, 2017 | | 2017 |
| Cytotoxic potential of the RG7388 MDM2-p53 binding antagonist and the GSK2830371 WIP1 inhibitor on MX-1 and MCF-7 human breast cancer cells V Manoharan, J Lunec, A Esfandiari, A Mahdi, CE Wu, M Zanjirband, ... CANCER RESEARCH 77, 2017 | | 2017 |
| MDM2 antagonists− a therapeutic approach for patients with hepatocellular carcinoma? A Mahdi, J Lunec, H Reeves European Journal of Cancer 1 (61), S44, 2016 | | 2016 |
| Bcl-2 Expression in CagA Strain H. Pylori Gastritis (Immunohistochemical and Insitu Hybridization Study) HH Ali, HA Hassan, BAA Hassan, TW Ali Iraqi Postgraduate Medical Journal 11 (1), 2012 | | 2012 |
| Iraqi JMS TW Ali, AK Mahdi, HH Ali, HA Hassan IRAQI JOURNAL OF MEDICAL SCIENCES, 160, 2000 | | 2000 |
